Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics
Sergey Brezgin,
Anastasiya Kostyusheva,
Natalia Ponomareva,
Ekaterina Bayurova,
Alla Kondrashova,
Anastasia Frolova,
Olga Slatinskaya,
Landysh Fatkhutdinova,
Georgy Maksimov,
Mikhail Zyuzin,
Ilya Gordeychuk,
Alexander Lukashev,
Sergey Makarov,
Alexander Ivanov,
Andrey A. Zamyatnin,
Vladimir Chulanov,
Alessandro Parodi,
Dmitry Kostyushev
Affiliations
Sergey Brezgin
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Anastasiya Kostyusheva
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Natalia Ponomareva
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Ekaterina Bayurova
Chumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences (Polio Institute), 108819 Moscow, Russia
Alla Kondrashova
Chumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences (Polio Institute), 108819 Moscow, Russia
Anastasia Frolova
Division of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia
Olga Slatinskaya
Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
Landysh Fatkhutdinova
School of Physics, ITMO University, Lomonosova 9, 191002 St. Petersburg, Russia
Georgy Maksimov
Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
Mikhail Zyuzin
School of Physics, ITMO University, Lomonosova 9, 191002 St. Petersburg, Russia
Ilya Gordeychuk
Chumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences (Polio Institute), 108819 Moscow, Russia
Alexander Lukashev
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Sergey Makarov
School of Physics, ITMO University, Lomonosova 9, 191002 St. Petersburg, Russia
Alexander Ivanov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
Andrey A. Zamyatnin
Division of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia
Vladimir Chulanov
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Alessandro Parodi
Division of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia
Dmitry Kostyushev
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Because of their high biocompatibility, biological barrier negotiation, and functionalization properties, biological nanoparticles have been actively investigated for many medical applications. Biological nanoparticles, including natural extracellular vesicles (EVs) and synthetic extracellular vesicle–mimetic nanovesicles (EMNVs), represent novel drug delivery vehicles that can accommodate different payloads. In this study, we investigated the physical, biological, and delivery properties of EVs and EMNVs and analyzed their ability to deliver the chemotherapeutic drug doxorubicin. EMNVs and EVs exhibit similar properties, but EMNVs are more effectively internalized, while EVs show higher intracellular doxorubicin release activity. In addition, these nanotherapeutics were investigated in combination with the FDA-approved drug hydroxychloroquine (HCQ). We demonstrate that HCQ-induced lysosome destabilization and could significantly increase nanoparticle internalization, doxorubicin release, and cytotoxicity. Altogether, these data demonstrate that, from the delivery standpoint in vitro, the internalization of EMNVs and EVs and their payload release were slightly different and both nanotherapeutics had comparable cytotoxic performance. However, the synthesis of EMNVs was significantly faster and cost-effective. In addition, we highlight the benefits of combining biological nanoparticles with the lysosome-destabilizing agent HCQ that increased both the internalization and the cytotoxic properties of the particles.